Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A subset of primary central nervous system vasculitis where disease is rapidly progressive after onset that is characterized by bilateral, multiple, large cerebral vessel lesions and multiple CNS infarctions.
Biomarker and diagnostic research for rapidly progressive primary central nervous system vasculitis has been reported in the published literature.
No clinical trials have been registered for rapidly progressive primary central nervous system vasculitis.
21 publications have been identified in PubMed for rapidly progressive primary central nervous system vasculitis. Research spans Case Report / Case Series (76%), Diagnostic / Biomarker (10%), and Review / Meta-Analysis (10%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 16 | 76% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 4:30 PM UTC
Testing and diagnosis research |
2 |
10% |
Research summaries | 2 | 10% |
Disease patterns and progression | 1 | 5% |
Gusatovic J (2026). [PMID: 42230004](https://pubmed.ncbi.nlm.nih.gov/42230004/). *BMJ Case Rep*. [Diagnostic / Biomarker]
Wong EWN (2026). [PMID: 41712248](https://pubmed.ncbi.nlm.nih.gov/41712248/). *JAMA ophthalmology*. [Case Report / Case Series]
Cosentino B (2026). [PMID: 41528071](https://pubmed.ncbi.nlm.nih.gov/41528071/). *Archivos argentinos de pediatria*. [Case Report / Case Series]
Huang S (2026). [PMID: 41205477](https://pubmed.ncbi.nlm.nih.gov/41205477/). *Diagnostic microbiology and infectious disease*. [Review / Meta-Analysis]
Sánchez Montenegro A (2026). [PMID: 41657869](https://pubmed.ncbi.nlm.nih.gov/41657869/). *Cureus*. [Case Report / Case Series]
Wang N (2026). [PMID: 41549248](https://pubmed.ncbi.nlm.nih.gov/41549248/). *BMC neurology*. [Case Report / Case Series]
Godsey L (2026). [PMID: 41545226](https://pubmed.ncbi.nlm.nih.gov/41545226/). *BMJ case reports*. [Case Report / Case Series]
Imamura D (2026). [PMID: 41833369](https://pubmed.ncbi.nlm.nih.gov/41833369/). *Rinsho Shinkeigaku*. [Case Report / Case Series]
Salvarani C (2026). [PMID: 42127334](https://pubmed.ncbi.nlm.nih.gov/42127334/). *Neurol Neuroimmunol Neuroinflamm*. [Case Report / Case Series]
Bashier S (2025). [PMID: 40927789](https://pubmed.ncbi.nlm.nih.gov/40927789/). *European journal of case reports in internal medicine*. [Case Report / Case Series]
AI-curated news mentioning rapidly progressive primary central nervous system vasculitis
Updated Aug 6, 2026
New French guidelines have been published for the diagnosis and management of primary central nervous system vasculitis. These guidelines aim to standardize care and improve outcomes for patients with this rare condition.
A case report details the use of percutaneous transluminal angioplasty to treat vertebral artery stenosis caused by primary central nervous system vasculitis. This study contributes to the understanding of treatment options for this rare condition.